HSCI News
A new therapy for treating Type 1 diabetes
Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D).
- Aging (9)
- ALS (12)
- Alzheimer's Disease (7)
- Bioengineering (30)
- Blood Diseases (51)
- Cancer (52)
- Cardiovascular Disease (24)
- Diabetes (30)
- Endocrine Disease (1)
- Eye Diseases (10)
- Fibrosis (6)
- Gastrointestinal Disease (6)
- Genetics/Epigenetics (24)
- Graft-Versus-Host Disease (1)
- Hearing Loss (4)
- Immunology (15)
- Kidney Disease (12)
- Liver Disease (6)
- Lung Disease (9)
- Multiple Sclerosis (1)
Media Inquiries
If you are a journalist looking for an expert to comment on stem cell research, please contact hsci.harvard.edu
If you want to learn about potential stem cell treatments, we encourage you to explore A Closer Look at Stem Cells, the blog of the International Society for Stem Cell Research (ISSCR)